Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey ; volume:12 ; number:1 ; day:24 ; month:4 ; year:2012 ; pages:1-10 ; date:12.2012
BMC cancer ; 12, Heft 1 (24.4.2012), 1-10, 12.2012
- Urheber
-
Kodama, Yuko
- Beteiligte Personen und Organisationen
-
Morozumi, Ryoko
Matsumura, Tomoko
Kishi, Yukiko
Murashige, Naoko
Tanaka, Yûji
Takita, Morihito
Hatanaka, Nobuyo
Kusumi, Eiji
Kami, Masahiro
Matsui, Akihiko
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-12-152
- URN
-
urn:nbn:de:1111-201603044133
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kodama, Yuko
- Morozumi, Ryoko
- Matsumura, Tomoko
- Kishi, Yukiko
- Murashige, Naoko
- Tanaka, Yûji
- Takita, Morihito
- Hatanaka, Nobuyo
- Kusumi, Eiji
- Kami, Masahiro
- Matsui, Akihiko
- SpringerLink (Online service)
Ähnliche Objekte (12)
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg
Solid lipid nanoparticles for increased oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Hairy-cell leukaemia
Hairy cell leukaemia
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg
Solid lipid nanoparticles for increased oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Hairy-cell leukaemia
Hairy cell leukaemia
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg
Solid lipid nanoparticles for increased oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Hairy-cell leukaemia
Hairy cell leukaemia
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy